Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 30.00 | |
2 mg | In stock | $ 40.00 | |
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 233.00 | |
50 mg | In stock | $ 459.00 | |
100 mg | In stock | $ 673.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively). |
Targets&IC50 | JAK2:77 nM (IC50), JAK1:17 nM (IC50), JAK3:6.9 μM (IC50) |
In vitro | PF-06700841 has good potency against IL6/pStat1 in the CD3+ cellular subset (IC50 of 81 nM), but lower inhibition of IL6/pSTAT3, again in the CD3+ cellular subset (IC50 of 641 nM). |
In vivo | PF-06700841 (oral administration; for 7 consecutive days; female Lewis rats) treatment significantly reduces paw volume increase in a dose-dependent manner[1]. |
Synonyms | PF-06700841 P-Tosylate |
Molecular Weight | 561.6 |
Formula | C25H29F2N7O4S |
CAS No. | 2140301-96-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 59 mg/mL (105.05 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Brepocitinib P-Tosylate 2140301-96-6 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK Janus kinase inhibit Brepocitinib PTosylate Inhibitor PF-06700841 P-Tosylate Brepocitinib P Tosylate inhibitor